MediScience's pre-cancer detection trial approved
This article was originally published in Clinica
Executive Summary
The US FDA has approved MediScience Technology's IDE submission to begin a Phase II trial of its CD Scan device for the detection of early-stage oral leukoplakia, a cancer of the mouth. CD Scan uses the company's patented fibreoptic probe that detects differences in the fluorescence spectra of normal and cancerous tissue.